Hong Kong Stock Movement: BIOSINO BIO-TEC fell by 10.56%, with active capital flow causing fluctuations

Hong Kong Stock Movement BIOSINO BIO-TEC fell 10.56%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry BeiGene fell 0.83%, with a trading volume of HKD 395 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. CanSino Biologics fell 1.16%, with a trading volume of HKD 363 million, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. 3SBio rose 0.44%. Based on recent key news: On November 12, Huatai Securities reduced its holdings in 3SBio by 1.5945 million shares, leading to a certain impact on market confidence in the stock. After the reduction, Huatai Securities' shareholding ratio decreased to 5.99%. On November 17, the closing price of 3SBio was HKD 33.1, down 3.72% from the previous trading day, with a trading volume of 18.883 million shares, indicating high market attention to the stock. Recently, investment banks have mainly rated 3SBio as a buy, with a target average price of HKD 41.18. Guosen Securities has given an outperform rating, showing long-term optimism in the stock. The biopharmaceutical industry has been active recently. Stocks with High Market Capitalization in the Industry Innovent Biologics fell 1.16%. Based on recent key news: On November 17, Innovent Biologics' stock price fell 1.57%, closing at HKD 90.8, with a trading volume of 7.9741 million shares and a trading volume of HKD 717 million. Despite JP Morgan increasing its holdings by 1.438757 million shares on November 11, raising its shareholding ratio to 5.06%, the stock price still fell, indicating a cautious market attitude towards the stock's short-term performance. Source: Zhitong Finance On November 11, JP Morgan increased its holdings in Innovent Biologics by 1.438757 million shares at a price of HKD 84.7327 per share, totaling approximately HKD 122 million. After the increase, the number of shares held was approximately 86.8411 million, with a shareholding ratio of 5.06%. This increase indicates that institutions are optimistic about the long-term prospects of Innovent Biologics. Source: Zhitong Finance Recently, investment banks have mainly rated Innovent Biologics as a buy, with 20 investment banks giving buy ratings in the past 90 days, and a target average price of HKD 114.79. Galaxy Securities has recently given a recommendation rating, showing market confidence in its future growth potential. Source: Zhitong Finance The biopharmaceutical industry has shown stable performance recently, with significant capital inflow